Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...1314151617181920212223...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Current Treatment Strategies and Risk Stratification for Oral Carcinoma () -  Jun 1, 2023 - Abstract #ASCO2023ASCO_7177;    
    In cisplatin-ineligible patients, docetaxel with postoperative radiation is supported by the best evidence. Other possible options include concurrent cetuximab, carboplatin/5FU, carboplatin/paclitaxel, or the use of accelerated radiation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Effect and imaging analysis of cetuximab combined with radiotherapy in patients with rectal carcinoma. (Pubmed Central) -  May 30, 2023   
    BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKIs. Treatment with cetuximab and radiotherapy can greatly reduce serum tumor marker levels in RC patients and bring them health benefits, and further studies will help establish a better solution for such patients.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, fulzerasib (GFH925) / GenFleet Therap
    Enrollment open, Trial primary completion date, Combination therapy, Metastases:  Efficacy and Safety of IBI351 in Combination With Sintilimab  (clinicaltrials.gov) -  May 30, 2023   
    P1,  N=144, Recruiting, 
    Treatment with cetuximab and radiotherapy can greatly reduce serum tumor marker levels in RC patients and bring them health benefits, and further studies will help establish a better solution for such patients. Not yet recruiting --> Recruiting | Trial primary completion date: May 2023 --> May 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal, Tumor microenvironment, IO biomarker:  The clinical relevance and prediction efficacy from therapy of tumor microenvironment related signature score in colorectal cancer. (Pubmed Central) -  May 26, 2023   
    Our findings suggested that the high TMERSS subtype may have a higher proportion of respondents to Cetuximab agent and immunotherapy, while the low TMERSS subtype may be more suitable for treatment with FOLFOX and FOLFIRI regimens. In conclusion, the TMERSS model may provide a partial reference for the prognosis evaluation of patients, the prediction of drug sensitivity, and the implementation of clinical decision-making.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  CA225200: PhII ICb With/Without Erbitux in MBC Pts (clinicaltrials.gov) -  May 26, 2023   
    P2,  N=154, Active, not recruiting, 
    In conclusion, the TMERSS model may provide a partial reference for the prognosis evaluation of patients, the prediction of drug sensitivity, and the implementation of clinical decision-making. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Combination therapy, Monotherapy, Metastases:  EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (clinicaltrials.gov) -  May 23, 2023   
    P2,  N=130, Active, not recruiting, 
    Completed --> Terminated; terminated at pre-planned futility analysis Trial completion date: Oct 2022 --> Oct 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Oral Cavity Squamous Cell Carcinoma: An Update of the Pharmacological Treatment. (Pubmed Central) -  May 16, 2023   
    Our results showed that nanotechnologies use to enhance the efficacy of anticancer drugs such as: cisplatin, paclitaxel, cetuximab, EGFR antagonists, MEK1/2 and immune check inhibitors combination could have promising anti-cancer activity. However, the paucity of available data on drugs suggests the urgent need to improve the pharmacological armamentarium for OCSCC treatment.
  • ||||||||||  NKTR-255 / Nektar Therap
    Trial completion, Enrollment change, Trial completion date, Combination therapy, Monotherapy:  Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov) -  May 16, 2023   
    P1b/2,  N=25, Completed, 
    However, the paucity of available data on drugs suggests the urgent need to improve the pharmacological armamentarium for OCSCC treatment. Active, not recruiting --> Completed | N=326 --> 25 | Trial completion date: Aug 2024 --> Mar 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  A single chain variable fragment-anticancer lytic peptide (scFv-ACLP) fusion protein for targeted cancer treatment. (Pubmed Central) -  May 15, 2023   
    Herein, we designed a fusion protein with a cetuximab-derived single-chain variable fragment targeting epidermal growth factor receptor (anti-EGFR scFv) and the anticancer lytic peptide (ACLP) ZXR2, connected by a linker (G S) and MMP2 cleavage site...This fusion protein caused cell membrane lysis as ZXR2, and showed improved stability in serum compared to ZXR2. These results suggest that scFv-ACLP fusion proteins may be potential anticancer drug candidates for targeted cancer treatment, which also provide a feasible idea for targeted drug design.
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  IPH2201-203: Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) -  May 12, 2023   
    P1b/2,  N=143, Completed, 
    An escalated dose of 74.8 Gy could mitigate the negative impact of large tumor volume but for some patients, even this intensified treatment was insufficient. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    USE OF A FOAMY-VIRUS VECTOR SYSTEM TO PRODUCE AN  (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1675;    
    Overall, we provide a proof of concept that allogeneic, in-house Fc?-CR-T cells derived from a non-pathogenic viral backbone such as the FV, could be a safe, efficient and affordable alternative to LV-derived vectors for immunotherapy. Our future aim is to further modify these Fc?-CR-T cells, by interfering with immune checkpoint molecules, in order to achieve better tumour penetration and tackle the anergy induced by the tumor microenvironment.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Blenrep (belantamab mafodotin) / GSK
    ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1241;    
    In aggregate, we demonstrate that CAR-T cell depletion strategies relying on a functional effector cellcompartment might be of limited relevance during the time period of intense lymphodepletion and/or for cell products (co-)targeting NK cells. Besides unspecific T cell inhibition with dasatinib or depletion with fludarabine and mafosfamide, the use of ADCs has the potential to control CAR-T cell associated toxicities in a CAR specific manner independent of the patient's immunological fitness.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Journal, Surgery:  Intraoperative indocyanine green clearance in liver surgery: a useful tool to promote parenchymal preservation? (Pubmed Central) -  May 12, 2023   
    Therefore, chemotherapy regimen was switched to FOLFIRI/cetuximab (12 cycles)...Postoperative course was uneventful and adjuvant capecitabine was administered (8 cycles)...However, eighteen months following surgery, she developed impairment of hepatic function and portal hypertension. Preoperative ICG administration could be helpful to intraoperatively detect patients that can develop late post hepatectomy impairment of hepatic function, especially following SIRT2 (REF2), and promote parenchymal preservation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Severe Isolated Hypocalcemia with Cetuximab & Irinotecan Chemotherapy (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2427;    
    Therapy for HC can be complex, involves short- and long-term interventions, and correction is critical. Serum Ca surveillance before and during CTX management of cancer patients may reveal more instances and provide insight into the exact mechanisms.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Dual Cause of Hypercalcemia: Can both multiple myeloma and paraneoplastic parathyroid-related hormone production occur simultaneously? (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_785;    
    At the time of evaluation in September 2022, she was actively on cetuximab chemotherapy and completed her initial radiation...The patient improved with medical management for the hypercalcemia and was started on dexamethasone for the multiple myeloma...Our patient had hypercalcemia due to high PTHrP from squamous cell carcinoma as well as newly diagnosed multiple myeloma. This case highlights the importance of recognizing that hypercalcemia may be multifactorial and a complete evaluation is needed to treat all causes appropriately.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, IO biomarker:  Antitumor effects of NK cells expanded by activation pre?processing of autologous feeder cells before irradiation in colorectal cancer. (Pubmed Central) -  May 8, 2023   
    To confirm the antitumor activity of the NK cells expanded by this method, the expanded NK cells were treated with cetuximab, radiotherapy, or a combination of cetuximab and radiotherapy in the presence of human colorectal cancer cells...Thus, in the present study, a novel method for high-purity activated NK cell expansion was developed using activated and irradiated PBMCs. In addition, combined radiotherapy and antibody-based immunotherapy with expanded NK cells may be an effective strategy to enhance the efficiency of treatment against colorectal cancer.